The impact of removing prior authorization for guideline-concordant maintenance inhaled medications for COPD: a population-based cohort study

Kate M. Johnson, Lucy Cheng, Kevin I. Duan, Michael R. Law

Open source

DOI
10.1016/j.chest.2026.10.035
Published
2026-11
Container
CHEST
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.chest.2026.10.035,
  title = {The impact of removing prior authorization for guideline-concordant maintenance inhaled medications for COPD: a population-based cohort study},
  author = {Kate M. Johnson and Lucy Cheng and Kevin I. Duan and Michael R. Law},
  year = {2026},
  journal = {CHEST},
  doi = {10.1016/j.chest.2026.10.035},
  url = {https://doi.org/10.1016/j.chest.2026.10.035}
}

RIS

TY  - JOUR
TI  - The impact of removing prior authorization for guideline-concordant maintenance inhaled medications for COPD: a population-based cohort study
AU  - Kate M. Johnson
AU  - Lucy Cheng
AU  - Kevin I. Duan
AU  - Michael R. Law
PY  - 2026
JO  - CHEST
DO  - 10.1016/j.chest.2026.10.035
UR  - https://doi.org/10.1016/j.chest.2026.10.035
ER  - 

APA

Johnson, K. M., Cheng, L., Duan, K. I., & Law, M. R. (2026). The impact of removing prior authorization for guideline-concordant maintenance inhaled medications for COPD: a population-based cohort study. CHEST. https://doi.org/10.1016/j.chest.2026.10.035

Source records